Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus abiraterone acetate and prednisone vs abiraterone acetate and prednisone in metastatic prostate cancer
2017-003364-12Phase 3Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Niraparib + abiraterone acetate + prednisone with Placebo + abiraterone acetate + prednisone (2 arms). Primary endpoint: Radiographic progression-free survival (rPFS). Status: unknown.
02
Drugs
niraparib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2017-003364-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003364-12.